Dolby Laboratories (DLB) Meta Tie Up Puts Fair Value Back In Focus

Dolby Laboratories (DLB) is back in focus after announcing an expanded partnership with Meta that brings Dolby Atmos and Dolby Vision deeper into Meta AI glasses, Instagram, and upcoming VR hardware.

For investors, the Meta announcement comes after a choppy year for Dolby Laboratories. The share price has slipped to US$58.03 and the 30 day share price return is down 12.14%, even though the 90 day share price return is up 10.64%. The 1 year total shareholder return has declined 17.09%, pointing to pressure on sentiment despite recent product launches and the September ESOP related shelf registration.

Scan beyond Dolby Laboratories to see how it stacks up against 30 high quality undervalued stocks that the Simply Wall St team has already surfaced for their mix of quality, cash flows, and balance sheet strength.

Bulls point to Dolby Laboratories’ Meta expansion and solid profitability, while bears focus on muted growth and rising costs. Which side does the valuation argue for as Dolby trades near US$58?

Most Popular Narrative: 26.5% Undervalued

Dolby Laboratories last traded at $58.03, while the most followed narrative pegs fair value at $79.00 using an 8.6% discount rate and a usage based earnings path.

Expanding Dolby Laboratories licensing beyond device OEMs into content and usage based models through the video distribution patent program is adding new royalty streams from major global streaming platforms, which can deepen revenue and support earnings over time. Growth in Dolby Atmos, Dolby Vision and imaging patents as a larger share of licensing, guided to roughly 15% year over year and approaching about half of licensing revenue in FY26, shifts the mix toward higher value formats that can support margins and overall earnings quality.

See why 16 investors see Dolby Laboratories as 27% undervalued.

Result: Fair Value of $79 (UNDERVALUED)

Still, the Dolby Laboratories story could change quickly if elevated component costs continue to squeeze lower end devices or if newer content and automotive royalties underwhelm.

Find out about the key risks to this Dolby Laboratories narrative.

Next Steps

Sentiment on Dolby Laboratories is clearly mixed, with solid profitability on one side and growth and cost concerns on the other. Move quickly and examine the data for yourself, then weigh both the potential upsides and the flagged issues by reviewing the 4 key rewards and 1 important warning sign.

Looking for more ideas beyond Dolby Laboratories?

Do not stop with Dolby Laboratories. Put a handful of fresh, data backed ideas on your radar now so you are not chasing them after the move.

• Target income stability by reviewing potential high yield candidates inside the 7 dividend fortresses and see which payouts align with your goals.
• Hunt for resilient balance sheets through the list of solid balance sheet and fundamentals (23 results) to focus on companies built to handle tougher conditions.
• Go off the beaten path with the 16 high quality undiscovered gems and spot quality businesses that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com